ARTICLE | Company News
Tarsa Therapeutics, Unigene deal
October 26, 2009 7:00 AM UTC
Newco Tarsa received an exclusive, worldwide license, excluding China, to develop and commercialize Unigene's oral calcitonin. The osteoclast inhibitor is in Phase III testing for osteoporosis, with data expected in 18 months. Unigene received a 25% stake in Tarsa and will be reimbursed $9 million in cash, in part for expenditures related to the Phase III trial. Unigene also is eligible for undisclosed milestones, plus royalties. ...